Perspective
Jul. 20, 2013
Until FDA acts, generic drug consumers left without remedy
The U.S. high court's recent rulings limiting generic drug manufacturers' liability exposure are perplexing given the purpose of the federal law preempting these claims. By Patricia L. Zlaket
Unfortunately for millions of consumers, the legal battles related to labeling for generic drugs rage on.
In 2011, the U.S. Supreme Court decision in PLIVA, Inc., et al. v. Mensing gave more power to drug companies - ruling that generic makers cannot be held responsible for failure to warn about a drug's side-effects, since the generic maker is only making a "copy" of the brand drug and must follow the brand na...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In